var data={"title":"Inotuzumab ozogamicin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Inotuzumab ozogamicin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/814657?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=inotuzumab-ozogamicin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Inotuzumab ozogamicin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50512498\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatotoxicity, including veno-occlusive disease:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Hepatotoxicity, including fatal and life-threatening veno-occlusive disease (VOD) (also known as sinusoidal obstruction syndrome) occurred in patients with relapsed or refractory acute lymphoblastic leukemia (ALL) who received inotuzumab ozogamicin. The risk of VOD was greater in patients who underwent HSCT after inotuzumab ozogamicin treatment; use of HSCT conditioning regimens containing 2 alkylating agents and last total bilirubin level &ge; upper limit of normal (ULN) before HSCT were significantly associated with an increased risk of VOD.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Other risk factors for VOD in patients treated with inotuzumab ozogamicin included ongoing or prior liver disease, prior HSCT, increased age, later salvage lines, and a greater number of inotuzumab ozogamicin treatment cycles.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Elevation of liver tests may require dosing interruption, dose reduction, or permanent discontinuation of inotuzumab ozogamicin. Permanently discontinue treatment if VOD occurs. If severe VOD occurs, treat according to standard medical practice.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Increased risk of post-hematopoietic stem cell transplant non-relapse mortality:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">There was higher post-hematopoietic stem cell transplant (HSCT) non-relapse mortality rate in patients receiving inotuzumab ozogamicin, resulting in a higher Day 100 post-HSCT mortality rate.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50546967\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Besponsa</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50512502\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Anti-CD22;</li>\n      <li>\n        Antineoplastic Agent, Antibody Drug Conjugate;</li>\n      <li>\n        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50546904\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute lymphoblastic leukemia, B-cell precursor (relapsed/refractory):</b>IV: Premedication is recommended prior to dosing. Prior to the first dose, cytoreduction to a peripheral blast count of &le;10,000/mm<sup>3</sup> with a combination of hydroxyurea, steroids, and/or vincristine is recommended for patients with circulating lymphoblasts.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cycle 1:</b> 0.8 mg/m<sup>2</sup> on day 1 and 0.5 mg/m<sup>2</sup> on days 8 and 15 of a 21-day treatment cycle (total dose/cycle 1: 1.8 mg/m<sup>2</sup>); treatment cycle may be extended to 4 weeks if complete remission (CR) is achieved, or CR with incomplete hematologic recovery (CRi) and/or to allow for recovery from toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Subsequent cycles:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients who achieve CR or CRi:</i> 0.5 mg/m<sup>2</sup> on days 1, 8 and 15 of a 28-day treatment cycle (total dose/cycle: 1.5 mg/m<sup>2</sup>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients who do NOT achieve CR or CRi:</i> 0.8 mg/m<sup>2</sup> on day 1 and 0.5 mg/m<sup>2</sup> on days 8 and 15 of a 28-day treatment cycle (total dose/cycle: 1.8 mg/m<sup>2</sup>); if CR or CRi is not achieved within 3 cycles, discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Treatment duration:</b> The recommended duration of treatment is 2 cycles for patients proceeding to hematopoietic stem cell transplant (HSCT); may consider a third cycle in patients who do not achieve CR or CRi and minimal residual disease (MRD) negativity after 2 cycles. For patients not proceeding to HSCT, may continue treatment for a maximum of up to 6 cycles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Premedication:</b> A corticosteroid, an antipyretic, and an antihistamine are recommended prior to dosing (observe for symptoms of infusion reaction during and for at least 1 hour after the end of the infusion).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Doses on days 8 and 15 may be varied by &plusmn;2 days (maintain a minimum of 6 days between doses). CR is defined as &lt;5% blasts in bone marrow and the absence of peripheral blood leukemic blasts, full recovery of peripheral blood counts (platelets &ge;100,000/mm<sup>3</sup> and ANC &ge;1,000/mm<sup>3</sup>) and resolution of any extramedullary disease. CRi is defined as &lt;5% blasts in bone marrow and the absence of peripheral blood leukemic blasts, incomplete recovery of peripheral blood counts (platelets &lt;100,000/mm<sup>3</sup> and/or ANC &lt;1,000/mm<sup>3</sup>) and resolution of any extramedullary disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991350\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 15 to 89 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however pharmacokinetics in this patient population are similar to those in patients with normal renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">End-stage renal disease (ESRD) with or without hemodialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988259\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatic impairment prior to treatment initiation:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Total bilirubin &le;1.5 times ULN and AST/ALT &le;2.5 times ULN: No initial dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Total bilirubin &gt;1.5 times ULN and/or AST/ALT &gt;2.5 times ULN: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatotoxicity during treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sinusoidal obstruction syndrome (also known as veno-occlusive disease) or other severe liver toxicity: Discontinue permanently.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Total bilirubin &gt;1.5 times ULN and AST<b>/</b>ALT &gt;2.5 times ULN: Interrupt treatment until recovery of total bilirubin to &le;1.5 times ULN and AST/ALT to &le;2.5 times ULN prior to each dose unless due to Gilbert syndrome or hemolysis. Permanently discontinue treatment if total bilirubin does not recover to &le;1.5 times ULN or AST/ALT does not recover to &le;2.5 times ULN. Refer to Dosing: Adjustment for Toxicity for dose modifications depending on duration of treatment interruption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50546897\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50546912\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">Modify the inotuzumab ozogamicin dose for toxicities; doses within a treatment cycle (eg, day 8 and/or day 15 doses) do not need to be interrupted due to neutropenia or thrombocytopenia; however, dosing interruptions within a cycle are recommended for nonhematologic toxicities. If a dose is reduced due to toxicity, do not re-escalate the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematologic toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Platelet count used for dosage modification should be independent of transfusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If ANC decreases, and the ANC prior to inotuzumab ozogamicin treatment was &ge;1,000/mm<sup>3</sup>, interrupt the next cycle of treatment until ANC recovers to &ge;1,000/mm<sup>3</sup>. Discontinue inotuzumab ozogamicin if low ANC persists for &gt;28 days and is suspected to be related to inotuzumab ozogamicin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If platelet count decreases, and the platelet count prior to inotuzumab ozogamicin treatment was &ge;50,000/mm<sup>3</sup>, interrupt the next cycle of treatment until platelets recover to &ge;50,000/mm<sup>3</sup>. Discontinue inotuzumab ozogamicin if low platelets persist for &gt;28 days and is suspected to be related to inotuzumab ozogamicin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If ANC or platelet counts decrease and ANC &lt;1,000/mm<sup>3</sup> and/or platelet count was &lt;50,000/mm<sup>3</sup> prior to inotuzumab ozogamicin treatment, then interrupt the next cycle of treatment until at least one of the following occurs:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>- </b>ANC and platelet counts recover to at least baseline levels for the prior cycle <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>- </b>ANC recovers to &ge;1,000/mm<sup>3</sup> and platelet count recovers to &ge;50,000/mm<sup>3 </sup><b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>- </b>Based on most recent bone marrow assessment, disease is stable or improved and the ANC and platelet count decrease is considered to be due to underlying disease (not considered to be an inotuzumab ozogamicin-related toxicity).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nonhematologic toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dose modifications depending on duration of treatment interruption due to nonhematologic toxicity:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If interruption is &lt;7 days (within a cycle): Interrupt the next dose (maintain a minimum of 6 days between doses).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If interruption is &ge;7 days: Omit the next dose within the cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If interruption is &ge;14 days: Once recovery is adequate, decrease the total inotuzumab ozogamicin dose by 25% for the subsequent cycle. If further dose modification is necessary, then reduce the number of doses to 2 per cycle for subsequent cycles. If a 25% decrease in the total dose followed by a decrease to 2 doses per cycle is not tolerated, then permanently discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If interruption is &gt;28 days: Consider permanently discontinuing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatotoxicity:</b> Refer to Dosing: Hepatic Impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Infusion reaction:</b> Interrupt infusion and institute appropriate medical management; depending on the severity of the reaction, consider discontinuing the infusion or administer steroids and antihistamines. For severe or life-threatening infusion reactions, discontinue permanently.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Other nonhematologic toxicity &ge; grade 2:</b> Interrupt treatment until recovery to grade 1 or pretreatment grade levels prior to each dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50546968\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Besponsa: 0.9 mg (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50546966\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50709981\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Available through specialty pharmacy distributors. Information and a distributor list is available from the manufacturer at 1-877-744-5675.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50546921\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Infuse over 1 hour (at a rate of 50 mL/hour). If refrigerated, allow to reach room temperature for ~1 hour prior to administration. Infuse at room temperature and protect from light during infusion. Infusion sets made of PVC (DEHP-or non-DEHP-containing), polyolefin (polypropylene and/or polyethylene), or polybutadiene are recommended for administration. An inline filter is not required during administration; however, if the diluted solution is filtered, polyethersulfone (PES)-, polyvinylidene fluoride (PVDF)-, or hydrophilic polysulfone (HPS)-based filters are recommended (do not use filters made of nylon or mixed cellulose ester). Do not mix or administer with other medications.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50546885\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50512504\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Acute lymphoblastic leukemia (relapsed/refractory):</b> Treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50546878\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Inotuzumab ozogamicin may be confused with gemtuzumab ozogamicin, ibritumomab</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50540233\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (35%), headache (28%), chills (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase (21% to 67%), hyperuricemia (4% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Increased serum lipase (9% to 32%), nausea (31%), abdominal pain (23%), diarrhea (17%), constipation (16%), vomiting (15%), increased serum amylase (5% to 15%), stomatitis (13%), decreased appetite (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (51%; grade 3: 14%; grade 4: 28%), neutropenia (49%; grade 3: 20% to 49%; grade 4: 27%), anemia (36%; grade &ge;3%: 24%), leukopenia (35%; grade &ge;3: 33%), hemorrhage (grade &ge;3: 5% to 33%), febrile neutropenia (26%; grade &ge;3: 26%), lymphocytopenia (18%; grade &ge;3: 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (71%), increased serum alkaline phosphatase (13% to 57%), increased serum ALT (49%), increased serum transaminases (26%), hepatic veno-occlusive disease (&le;23%), hyperbilirubinemia (21%), hepatotoxicity (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (48%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (32%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Prolonged Q-T interval on ECG (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distention (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bone marrow failure (2%; includes bone marrow failure, febrile bone marrow aplasia), tumor lysis syndrome (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Ascites (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (anti-inotuzumab antibodies: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Infusion related reaction (2%; grade 2: 2%; includes hypersensitivity)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined: Infection: Bacterial infection, fungal infection, viral infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50512505\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50546883\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; <b>Bone marrow suppression: </b>Hematologic toxicity, including thrombocytopenia and neutropenia commonly occur (including grades 3 and 4). Neutropenic fever occurred in over one-fourth of patients; may be life-threatening. For patients who were in complete remission (CR) or CR with incomplete hematologic recovery (CRi) at the end of treatment, the time to platelet recovery (&gt;50,000/mm<sup>3</sup>) was &gt;45 days after the last dose in some patients. Complications associated with myelosuppression (including infections and bleeding/hemorrhagic events) have been observed. Monitor complete blood counts prior to each dose and monitor for signs and symptoms of effects of myelosuppression during treatment; may require treatment interruption, dose reduction, or permanent discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>&bull; Hemorrhage:</b> Hemorrhagic events associated with thrombocytopenia have been reported, including grades 3 or 4 hemorrhagic events and one grade 5 (fatal) intra-abdominal hemorrhage. The most common hemorrhagic event was epistaxis. Monitor for signs and symptoms of bleeding/hemorrhage during treatment; may require treatment interruption, dose reduction, or permanent discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; <b>Hepatotoxicity: [US Boxed Warning]: </b><b>Hepatotoxicity, including severe, life-threatening, and sometimes fatal sinusoidal obstructions syndrome (formerly called veno-occlusive disease [VOD]) has occurred in patients with relapsed or refractory acute lymphoblastic leukemia (ALL) who received inotuzumab ozogamicin. The risk of VOD was greater in patients who received a hematopoietic stem cell transplant (HSCT) following inotuzumab ozogamicin treatment. The use of HSCT conditioning regimens containing 2 alkylating agents (eg, busulfan in combination with other alkylating agents) and a total bilirubin level &ge; upper limit of normal (ULN) before HSCT were significantly associated with increasing the risk of VOD. Other risk factors for VOD associated with inotuzumab ozogamicin included ongoing or prior liver disease, prior HSCT, increased age, later salvage lines, and a higher number of inotuzumab ozogamicin treatment cycles.</b> <b>Liver function test elevations may require treatment interruption, dose reduction, or permanent discontinuation; discontinue permanently if VOD occurs. </b>Patients with a history of VOD or who have serious ongoing hepatic liver disease (eg, cirrhosis, nodular regenerative hyperplasia, active hepatitis) are at an increased risk for worsening of liver disease, including developing VOD, following inotuzumab ozogamicin therapy. VOD was reported up to 56 days after the last dose during treatment or during follow-up without an intervening HSCT. For patients receiving HSCT after inotuzumab ozogamicin, the median time to onset of VOD was 15 days (range: 3 to 57 days). Due to the VOD risk, the recommended treatment duration with inotuzumab ozogamicin is 2 cycles in patients proceeding to HSCT; an additional cycle may be considered for patients not in CR or CRi and MRD negativity after 2 cycles. For patients not proceeding to HSCT, the recommended maximum is 6 cycles. Monitor closely for signs and symptoms of VOD (eg, total bilirubin elevations, hepatomegaly [may be painful], rapid weight gain, and ascites). For patients who proceed to HSCT, monitor liver tests closely during the first month post-HSCT. Utilize standard medical management for severe VOD. Other hepatotoxicity events have been reported, including grades 3 and 4 AST, ALT, and total bilirubin elevations. Monitor liver function tests (ALT, AST, total bilirubin, and alkaline phosphatase) prior to and following each inotuzumab ozogamicin dose in all patients. Elevations of liver function tests may require dosing interruption, dose reduction, or permanent discontinuation of inotuzumab ozogamicin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>&bull; Hypersensitivity: </b>Hypersensitivity reactions have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>&bull; Infections:</b> Infections, including serious infections (some life-threatening or fatal), were reported in nearly half of patients treated with inotuzumab ozogamicin. Fatal infections, including pneumonia, neutropenic sepsis, sepsis, septic shock, and pseudomonal sepsis, have been reported; bacterial, viral, and fungal infections occurred. Monitor for signs and symptoms of infection during treatment. Administer prophylactic anti-infectives and employ surveillance testing during and after treatment. Severe infection may require treatment interruption, dose reduction, or permanent discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>&bull; Infusion reactions:</b> Grade 2 infusion related reactions were reported with inotuzumab ozogamicin administration in a small percentage of patients. Infusion reactions (eg, fever, chills, rash, dyspnea) usually occurred in cycle 1 shortly after the end of the infusion and resolved spontaneously or with medical management. Premedicate with a corticosteroid, antipyretic, and antihistamine prior to dosing. Monitor closely during the infusion and for at least 1 hour after the end of the infusion for potential reactions. If an infusion reaction occurs, interrupt infusion and manage appropriately. Depending on the severity, consider discontinuing the infusion or administering corticosteroids and antihistamines. Permanently discontinue if a severe or life-threatening infusion reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>&bull; QT prolongation:</b> Increases in the corrected QT interval of &ge;60 msec from baseline were observed in a small number of patients (including grade 2 prolongation in some patients), although none had QTcF values greater than 500 msec. There were no grade 3 or higher QT prolongations or cases of torsades de pointes reported. Use inotuzumab ozogamicin with caution in patients with a history of (or predisposition for) QTc prolongation, patients taking drugs known to prolong the QT interval, and/or in patients with electrolyte abnormalities. Obtain ECG and electrolytes prior to treatment initiation, after initiation of any drug known to prolong QTc, and periodically as clinically indicated during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease related concerns: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; <b>Hematopoietic stem cell transplant: [US Boxed Warning]: </b><b>A higher post-HSCT non-relapse mortality rate was observed in patients who received inotuzumab ozogamicin, resulting in a higher Day 100 post-HSCT mortality rate. </b>The most common causes of post-HSCT non-relapse mortality included VOD and/or infection. Among patients with ongoing VOD, multiorgan failure or infection resulting in fatality occurred. Monitor closely for toxicities post-HSCT, including signs/symptoms of infection and VOD.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>&bull; Drug-drug interactions:</b> Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50553602\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50553599\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=114511&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50546880\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Based on the mechanism of action and information from animal reproduction studies, inotuzumab ozogamicin may be expected to cause adverse events if used during pregnancy. Pregnancy status should be evaluated prior to therapy. Women of reproductive potential should use effective contraception during therapy and for at least 8 months after the last dose. Effective contraception should also be used for at least 5 months after the last dose when treating males who have female partners of reproductive potential.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Inotuzumab ozogamicin may impair fertility in males and females of reproductive potential.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50546882\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if inotuzumab ozogamicin is present in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breastfeeding is not recommended by the manufacturer during therapy and for at least 2 months after the last dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50546924\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Complete blood counts (prior to each dose), liver function tests including ALT, AST, total bilirubin, and alkaline phosphatase (prior to and following each dose); for patients who proceed to HSCT, monitor liver function tests closely during the first month post-HSCT, then less frequently thereafter, according to standard medical practice; electrolytes (prior to treatment initiation, after initiation of any drug known to prolong QTc, and periodically as clinically indicated during treatment), pregnancy status (prior to treatment in females of reproductive potential). Obtain ECG (prior to treatment initiation, after initiation of any drug known to prolong QTc, and periodically as clinically indicated during treatment).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monitor closely for signs and symptoms of VOD (eg, hepatomegaly with or without pain, rapid weight gain, ascites); monitor for signs/symptoms of effects of myelosuppression (bleeding, hemorrhage, infection) during treatment; monitor closely during the infusion and for at least 1 hour after the end of the infusion for the potential infusion reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50546889\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inotuzumab ozogamicin is a humanized CD22-directed monoclonal antibody-drug conjugate which is composed of the IgG4 kappa antibody inotuzumab (which is specific for human CD22), a calicheamicin component (a cytotoxic agent that causes double-stranded DNA breaks), and an acid-cleavable linker that covalently binds the calicheamicin to inotuzumab. After the antibody-drug conjugate binds to CD22, the CD22-conjugate complex is internalized, and releases calicheamicin. Calicheamicin binds to the minor groove of DNA to induce double strand cleavage and subsequent cell cycle arrest and apoptosis (Kantarjian 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50546890\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Body surface area was found to significantly affect disposition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: ~12 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Calicheamicin: ~97% bound to human plasma proteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Calicheamicin: Primarily via nonenzymatic reduction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life, elimination: 12.3 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Clearance (steady state): 0.0333 L/hour</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50643689\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Besponsa Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.9 mg (1): $22,440.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50573314\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Besponsa (AT, CZ, DE, DK, EE, GB, HR, HU, LT, LV, PL, PT, RO, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Besponsa (inotuzumab ozogamicin) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. <i>N Engl J Med</i>. 2016;375(8):740-753. doi: 10.1056/NEJMoa1509277.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/inotuzumab-ozogamicin-drug-information/abstract-text/27292104/pubmed\" target=\"_blank\" id=\"27292104\">27292104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    The National Institute for Occupational Safety and Health (NIOSH) notice. Centers for Disease Control and Prevention website. <a href=\"https://www.cdc.gov/niosh/docs/2016-161/default.html\" target=\"_blank\">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2017. Accessed October 9, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed August 24, 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 114511 Version 20.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F50512498\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F50546967\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F50512502\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F50546904\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991350\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988259\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F50546897\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F50546912\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F50546968\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F50546966\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F50709981\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F50546921\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F50546885\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F50512504\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F50546878\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F50540233\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F50512505\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F50546883\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F50553602\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F50553599\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F50546880\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F50546882\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F50546924\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F50546889\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F50546890\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F50643689\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F50573314\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/114511|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=inotuzumab-ozogamicin-patient-drug-information\" class=\"drug drug_patient\">Inotuzumab ozogamicin: Patient drug information</a></li></ul></div></div>","javascript":null}